• IAC: A phase IV open-label evaluation of safety and tolerability of coformulated bictegravir/emtricitabine/tenofovir alafenamide for post-exposure prophylaxis following potential exposure to HIV-1 - (08/11/22)
   
  
• IAC: Supporting Achievement of the State of Georgia's 25% HIV Incidence Reduction Target Among MSM: A Mathematical Model to Evaluate the Potential Impact of Long-acting Pre-exposure Prophylaxis in Atlanta - (08/11/22)
   
  
• IAC: Assessment of cardiovascular health using the "Life's Simple 7" among the Canadian HIV and Aging Cohort study participants: a cross-sectional observational study - (08/11/22)
   
  
• IAC: Risk factors linked to age-related comorbidities among people living with HIV aged over 40 years - (08/11/22)
   
  
• IAC: Advanced HIV infection in the US: immune response to ART initiation - (08/11/22)
   
  
• IAC: Audience Segmentation of Preferences for Long-Acting Injectable PrEP Among U.S. MSM: A Latent Class Analysis - (08/11/22)
   
  
• IAC: Willingness & Preferences for Long-Acting Injectable PrEP Among US Men Who Have Sex with Men: A discrete choice experiment - (08/11/22)
   
  
• First Demonstration Project of Long-Acting Injectable Antiretroviral Therapy for Persons With and Without Detectable HIV Viremia in an Urban HIV Clinic - (07/28/22)
   
  
• IAC: High prevalence of asymptomatic Omicron carriage and correlation with CD4 T cell count among adults with HIV enrolling in COVPN 3008 Ubuntu clinical trial in sub-Saharan Africa - (08/10/22)
   
  
• IAC: Incidence and disease severity of non-alcoholic fatty liver disease among people living with HIV in Thailand - (08/09/22)
   
  
• IAC: HIV in 2022 and beyond: A view from NIAID - non-adherence, disengagement from care, PrEP, vaccine - cure research - (08/09/22)
   
  
• IAC: Bacterial translocation of LPS is associated with lower cognitive abilities in men living with HIV receiving antiretroviral therapy - (08/09/22)
   
  
• IAC: Use of the Patient Generated Index to identify physical health challenges among people living with HIV - (08/09/22)
   
  
• IAC: Early Implementation and Clinical Outcomes of Long-Acting Injectable Cabotegravir and Rilpivirine in a Safety-Net Clinic - (08/09/22)
   
  
• IAC: Assessment of cardiovascular health using the "Life's Simple 7" among the Canadian HIV and Aging Cohort study participants: a cross-sectional observational study - (08/09/22)
   
  
• IAC: Burden of chronic comorbidities among people living with and without HIV: disability-adjusted life years in British Columbia, Canada - (08/09/22)
   
  
• IAC: Selection of Cabotegravir Dosing Regimens For HIV Treatment and Pre-Exposure Prophylaxis (PrEP) in Adolescents by Leveraging Adult Data - (08/09/22)
   
  
• IAC: Association of prenatal PrEP exposure with neurodevelopmental and growth outcomes beyond 24 months among Kenyan children - (08/09/22)
   
  
• IAC: Determinants of long-term survival in late HIV diagnosed individuals: the PISCIS Cohort study - (08/09/22)
   
  
• IAC: High HIV incidence and mortality in a multi-site cohort of transgender women in the eastern and southern United States - (08/09/22)
   
  
• IAC: Prevalence of adverse birth outcomes and external birth defects among women living with HIV in Malawi - (08/09/22)
   
  
• IAC: Chronic injection opioid use increases the systemic inflammation and T cell immune activation in virally suppressed people living with HIV - each separately HIV & Opioid Use increase immune activation, inflammation - (08/09/22)
   
  
More HIV Articles...
 

• HEPATITIS D INFECTION: who should be screened AASLD 2018 HBV Guidelines - (05/27/22)
   
  
• Hepatitis D Changing Context Global Prevalence - (02/10/22)
   
  
• EASL: Efficacy and Safety of Bulevirtide Monotherapy Given at 2 mg or 10 mg Dose Level Once Daily for Treatment of Chronic Hepatitis Delta: Week 48 Primary Endpoint Results From a Phase 3 Randomized, Multicenter, Parallel Design Study - (06/24/22)
   
  
• EASL: Compassionate use of subcutaneous REP 2139-Mg in cirrhotic HBV / HDV coinfection - (07/18/22)
   
  
More Hep D Articles...
 

• IAC: Putting HBV/HCV Testing and Treatment in HIV Clinics Has Benefits in Vietnam - Mark Mascolini - (08/03/22)
   
  
• Sofosbuvir-velpatasvir-voxilaprevir in adolescents 12 to 17 years old with HCV infection - (07/25/22)
   
  
• EASL: Early post liver transplant rescue treatment with sofosbuvir/velpatasvir/voxilaprevir in patients experienced to NS5A-inhibitors - (07/18/22)
   
  
• EASL: Approaches for a Hepatitis C-free city: preliminary results - (07/18/22)
   
  
• EASL: A cluster randomized controlled study of secondary distribution of HCV self-test to support micro-elimination in Karachi, Pakistan - (07/18/22)
   
  
• EASL: From extensive to intensive screening, co-operation model of hepatitis C elimination in out-patients and people who inject drug population in southwest of China - (07/18/22)
   
  
• EASL: Improved recurrence-free survival rates in patients with HCV-related hepatocellular carcinoma and sustained virological response to direct-acting antivirals - (07/18/22)
   
  
• EASL: Hepatocellular carcinoma risks of liver fibrosis changes after viral eradication in chronic hepatitis C patients - (07/18/22)
   
  
More Hep C Articles...
 

• IAC: HIV/HBV coinfection in pregnancy and response to antiretroviral therapy - (08/09/22)
   
  
• IAC: Week 48 of a phase 3 randomized controlled trial of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) vs dolutegravir + emtricitabine/ tenofovir disoproxil fumarate (DTG+F/TDF) as initial treatment in HIV/HBV-coinfected adults (ALLIANCE) - Mark Mascolini - (07/30/22)
   
  
• EASL: Phase 1b/2a study of heterologous ChAdOx1-HBV/MVA-HBV therapeutic vaccination (VTP-300) as monotherapy and combined with low-dose nivolumab in virally-suppressed patients with CHB on nucleos(t)ide analogues - (07/25/22)
   
  
• EASL: Mechanistic pharmacokinetics/pharmacodynamics modelling of the simultaneous effects of bepirovirsen on hepatitis B surface antigen and alanine transaminase changes in chronic hepatitis B patients: Phase 2b analysis to inform Phase 3 decision-making - (07/25/22)
   
  
• EASL: Efficacy and safety of bepirovirsen in patients with chronic hepatitis B virus infection on stable nucleos(t)ide analogue therapy: interim results from the randomised Phase 2b B-Clear study - (07/25/22)
   
  
• EASL: Bepirovirsen, antisense oligonucleotide (ASO) against hepatitis B virus (HBV), harbors intrinsic immunostimulatory activity via toll-like receptor 8 (TLR8) preclinically, correlating with clinical efficacy from the Phase 2a study - (07/25/22)
   
  
• EASL: Combination treatment of a PAPD5/7 inhibitor with an antisense oligonucleotide bepirovirsen with concurrent dosing shows additive HBsAg decreases in the AAV-HBV mouse model - (07/25/22)
   
  
More Hep B Articles...
 

List not necessarily listed here in order of date being held.